Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bluebird Bio Sings Cheerily Of Its "Biggest ASH Ever"

Executive Summary

Company highlights LentiGlobin sickle cell and beta thalassemia data updates in investor call about the upcoming ASH meeting, which will feature 11 presentations across its clinical and preclinical programs.

You may also be interested in...

Bluebird 'Turns A Corner' With Lentiglobin Gene Therapy, Tests Remain

Updated results of studies of its Lentiglobin gene therapy using bluebird's new manufacturing process presented at the EHA meeting are encouraging but the real test will be in the longevity of its effects and the strength of its surrogate marker.

Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights

Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts